BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 37358863)

  • 21. [Pathological features and immune microenvironment in HER-2 intratumoral heterogeneous breast cancers].
    Yang YL; Song YM; Xue HQ; Sun H; Li YQ; Qian XL; Jiao J; Li KP; Zhang H; Guo XJ
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):165-169. PubMed ID: 36781238
    [No Abstract]   [Full Text] [Related]  

  • 22. Expression of programmed death-1 in sentinel lymph nodes of breast cancer.
    Tatara T; Mukohara T; Shimono Y; Yamasaki T; Imamura Y; Funakoshi Y; Toyoda M; Kiyota N; Takao S; Kono S; Kakeji Y; Minami H
    J Surg Oncol; 2018 May; 117(6):1131-1136. PubMed ID: 29193094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intratumoral heterogeneity of macrophages and fibroblasts in breast cancer is associated with the morphological diversity of tumor cells and contributes to lymph node metastasis.
    Tashireva LA; Denisov EV; Gerashchenko TS; Pautova DN; Buldakov MA; Zavyalova MV; Kzhyshkowska J; Cherdyntseva NV; Perelmuter VM
    Immunobiology; 2017 Apr; 222(4):631-640. PubMed ID: 27916281
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
    Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
    Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
    Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
    Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation study between the magnetic resonance imaging features of breast cancer and expression of immune molecular subtypes.
    Long N; Ran C; Sun J; Hao CJ; Sui YB; Li J; Shi YX; Zou ZX; Qu YH
    Eur Rev Med Pharmacol Sci; 2020 Nov; 24(22):11518-11527. PubMed ID: 33275218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa.
    Hadgu E; Seifu D; Tigneh W; Bokretsion Y; Bekele A; Abebe M; Sollie T; Merajver SD; Karlsson C; Karlsson MG
    BMC Womens Health; 2018 Feb; 18(1):40. PubMed ID: 29444670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of epithelial-mesenchymal transition process during breast cancer progression - the impact of molecular subtype and stromal composition.
    Markiewicz A; Topa J; Popęda M; Szade J; Skokowski J; Wełnicka-Jaśkiewicz M; Żaczek A
    Acta Biochim Pol; 2021 Aug; 68(3):385-392. PubMed ID: 34432400
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Yes-associated protein (YAP) is differentially expressed in tumor and stroma according to the molecular subtype of breast cancer.
    Kim SK; Jung WH; Koo JS
    Int J Clin Exp Pathol; 2014; 7(6):3224-34. PubMed ID: 25031743
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach.
    Bareche Y; Buisseret L; Gruosso T; Girard E; Venet D; Dupont F; Desmedt C; Larsimont D; Park M; Rothé F; Stagg J; Sotiriou C
    J Natl Cancer Inst; 2020 Jul; 112(7):708-719. PubMed ID: 31665482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study.
    Cimino-Mathews A; Ye X; Meeker A; Argani P; Emens LA
    Hum Pathol; 2013 Oct; 44(10):2055-63. PubMed ID: 23701942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer.
    Bonneau C; Eliès A; Kieffer Y; Bourachot B; Ladoire S; Pelon F; Hequet D; Guinebretière JM; Blanchet C; Vincent-Salomon A; Rouzier R; Mechta-Grigoriou F
    Breast Cancer Res; 2020 Jul; 22(1):76. PubMed ID: 32665033
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In situ imaging for tumor microbiome interactions via imaging mass cytometry on single-cell level.
    Feng Z; Hu Y; Wang X; Li Y; Yu Y; He J; Li H; Zhang T; Zhang L; Shen G; Ding X
    Cytometry A; 2022 Aug; 101(8):617-629. PubMed ID: 35301803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reproductive Risk Factors Associated with Breast Cancer Molecular Subtypes among Young Women in Northern China.
    Wang JM; Wang J; Zhao HG; Liu TT; Wang FY
    Biomed Res Int; 2020; 2020():5931529. PubMed ID: 32337260
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status.
    Glajcar A; Szpor J; Hodorowicz-Zaniewska D; Tyrak KE; Okoń K
    Virchows Arch; 2019 Jul; 475(1):13-23. PubMed ID: 31016433
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes - an observational cohort study in Sweden.
    Lindman H; Wiklund F; Andersen KK
    BMC Cancer; 2022 Sep; 22(1):1006. PubMed ID: 36138404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential distribution of microRNAs in breast cancer grouped by clinicopathological subtypes.
    Li JY; Jia S; Zhang WH; Zhang Y; Kang Y; Li PS
    Asian Pac J Cancer Prev; 2013; 14(5):3197-203. PubMed ID: 23803104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-Stroma-Inflammation Networks Promote Pro-metastatic Chemokines and Aggressiveness Characteristics in Triple-Negative Breast Cancer.
    Liubomirski Y; Lerrer S; Meshel T; Rubinstein-Achiasaf L; Morein D; Wiemann S; Körner C; Ben-Baruch A
    Front Immunol; 2019; 10():757. PubMed ID: 31031757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoints in aggressive breast cancer subtypes.
    Zawlik I; Gablo N; Szymanska B; Pawlowska Z; Chudobinski C; Chalubinska-Fendler J; Morawiec Z; Zielinska-Blizniewska H; Morawiec-Sztandera A; Kolacinska A
    Neoplasma; 2016; 63(5):768-73. PubMed ID: 27468881
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.